Ofer Haviv: So, for this year, one of the reasons that we raised money, it was also to support this growing demand in working capital. According to our estimation, after we will go through this round with the $11 million seed supply and with current financial position of Evogene, I don’t think that we will need additional capital. And maybe if we’ll do so, based on purchase order that we might even — if needed, we can take a loan from the bank’s credit in order to support the seed production. I think that this year, we felt that maybe the right thing is to raise money in order to do so. In the future, I intend to believe that — or that we will have enough from our internal resources or that if we need to use some credit from the bank, I believe that this is another option in order to fund the working capital needed.
Brett Reiss: Great. Thank you for that answer. A different question. The collaborations you’re working on with companies in areas not covered by your subsidiaries, do you have — could you share with us? Do you have a kind of template of what the structure of these potential deals and collaborations will look like?
Ofer Haviv: Yes. I can give you two examples. One ongoing discussion that we have advancing nicely is actually in the area of food tech. And here, we are talking about producing a protein in plant, protein that today, we all consume through eating meat. So, we would like to use — there’s specific investors and companies that are interested in this field of protein production in plant to replace a mammalian protein that we are all consuming. So, this is one field. And here, you can imagine that we can use our GeneRator AI technology and also maybe in a certain way also ChemPass AI in order to identify the genes, the genomic mechanism that you would like to improve in order to produce those proteins. Another example is related to MicroBoost.
Animals such as chicken and maybe others, they also suffer from different types of problems that you can treat them using microbes, and we might enter to some relationships in the field that we are using our MicroBoost AI tech engine also in identify microbes that can improve animal cells. So this is another example. But there are many other opportunities. This is just a few that currently under discussion, but there is much more that we are now pushing forward.
Brett Reiss: Great. Thank you very much for the opportunity to ask questions. And carry on, sir.
Ofer Haviv: Thank you very much. I appreciate it.
Operator: [Operator Instructions] There are no further questions at this time. Before I ask Mr. Ofer Haviv to go ahead with his closing statement, I would like to remind participants that a replay of this call is scheduled to begin 2 hours after the conference. In the U.S., please call 1-888-326-9310. In Israel, please call 03-9255-901. Internationally, please call 9723-9255-901. Mr. Haviv, would you like to make your concluding statement?
Ofer Haviv: Yes. Thank you. So, thank you all for joining the call today. It was a really tremendous quarter. We all look forward to updating you on our progress in our next call. Thank you.
Operator: Thank you. This concludes Evogene’s second quarter 2023 results conference call. Thank you for your participation. You may go ahead and disconnect.
